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Validations of apomorphine-induced BOLD activation correlations in
hemiparkinsonian rhesus macaques
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Identiﬁcation of Parkinson's disease at the earliest possible stage of the disease may provide the best opportunity
for the use of disease modifying treatments. However, diagnosing the disease during the pre-symptomatic period
remains an unmet goal. To that end, we used pharmacological MRI (phMRI) to assess the function of the corticobasal ganglia circuit in a non-human primate model of dopamine deﬁciency to determine the possible relationships between phMRI signals with behavioral, neurochemical, and histological measurements. Animals
with unilateral treatments with the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), that
expressed stable, long-term hemiparkinsonism were challenged with the dopaminergic receptor agonist, apomorphine, and structure-speciﬁc phMRI blood oxygen level-dependent (BOLD) activation responses were
measured. Behavioral, histopathological, and neurochemical measurements were obtained and correlated with
phMRI activation of structures of the cortico-basal ganglia system. Greater phMRI activations in the basal
ganglia and cortex were associated with slower movement speed, decreased daytime activity, or more pronounced parkinsonian features. Animals showed decreased stimulus-evoked dopamine release in the putamen
and substantia nigra pars compacta and lower basal glutamate levels in the motor cortex on the MPTP-lesioned
hemisphere compared to the contralateral hemisphere. The altered neurochemistry was signiﬁcantly correlated
with phMRI signals in the motor cortex and putamen. Finally, greater phMRI activations in the caudate nucleus
correlated with fewer tyrosine hydroxylase-positive (TH+) nigral cells and decreased TH+ ﬁber density in the
putamen. These results reveal the correlation of phMRI signals with the severity of the motor deﬁcits and pathophysiological changes in the cortico-basal ganglia circuit.

1. Introduction

Pharmacological MRI (phMRI) has been increasingly used as a
neuroimaging technique to investigate region-speciﬁc brain activity
associated with the administration of CNS-active drugs (Breiter et al.,
1997; Grasby et al., 1993; Lahti et al., 1995). As an imaging modality,
phMRI has a number of advantages related to molecular, structural, and
functional neuroimaging that are rapidly expanding the neurobiological
understanding of the complexities of PD. phMRI holds the promise of
providing early indications of the pharmacodynamic activity of novel
CNS-targeted compounds in a safe, non-invasive manner through blood
oxygenation level dependent (BOLD) imaging in experimental animals
(Andersen et al., 2015; Zhang et al., 2018), and in humans (Barber
et al., 2017; Nemoto et al., 2017). As a result, signiﬁcant eﬀort has been

Identiﬁcation of Parkinson's disease (PD) at the earliest possible
stage of the disease may provide the best opportunity for the use of
disease modifying treatments. However, correctly diagnosing the disease during the pre-symptomatic period remains diﬃcult. This is, in
part, because of the absence of predictive, non-invasive, in vivo tests for
PD and because PD symptoms resemble symptoms of other neurological
conditions. Moreover, the prevalence of both parkinsonian symptoms
and PD, per se, increases with age. The ideal diagnostic test would
conﬁrm the presence of prodromal PD and provide some information
about the lead time to motoric symptoms and the rate of progression.
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these animals and provide the basis for correlative analyses.

devoted to implementing phMRI as a translational research tool to
develop novel CNS compounds (Bifone and Gozzi, 2012; Wise and
Tracey, 2006) and to study neurological disorders (Andersen et al.,
2015; Seibyl et al., 2012; Weiller et al., 2006). Drug-induced pharmacodynamic responses detected from alterations in BOLD signals or relative cerebral blood volume/ﬂow (rCBV/rCBF) can serve as imaging
biomarkers to delineate the central eﬀect of drug actions
(Bhattacharyya et al., 2017; Ghariq et al., 2014; Jann et al., 2015; Tak
et al., 2015). In addition, phMRI has been used to study several key
neurotransmitter systems. Collectively, these studies have highlighted
the value of phMRI to elucidate neurobiological mechanisms of drug
actions to gain a better understanding of PD (Seibyl et al., 2012).
However, the clinical use of phMRI techniques as a tool for the early
diagnosis and clinical progression of PD is still lagging compared with
other modalities like positron emission tomography (PET) or single
photon emission computed tomography (SPECT), possibly because the
underlying neurophysiological mechanism(s) of phMRI signals are not
fully understood. Consequently, determining the relationships between
phMRI BOLD-activation and disease-related changes in neurobiology
and neurophysiology may lead to a more integrated and comprehensive
understanding of PD (Weingarten et al., 2015). Pharmacological neuroimaging as it relates to dopamine terminal degeneration could serve
important and unique roles in both earlier and later stages of the disease. In the early stages, neuroimaging might potentially allow diagnosis in the prodromal state. In the later stages, it might help with
elucidating pathology relevant to new drug development.
In the present study, the nonselective dopamine D1/D2 receptor
agonist apomorphine (APO; currently used as an FDA-approved PD
treatment) was used to stimulate the dopaminergic systems in animals
with stable, long-term MPTP-induced parkinsonism. The phMRI responses in the cortico-basal-ganglia-cortical circuit were directly correlated with a variety of in vivo measurements including behavioral
responses, in vivo microdialysis measurements of dopamine (DA)
function, and electrochemical recordings of resting glutamate levels.
Additional comparisons were made with postmortem data including
dopaminergic neuron counts in the substantia nigra (SN) pars compacta
(SNc) and ﬁber density in the striatum. These experiments were all
designed to test the hypothesis that phMRI signals (BOLD responses)
correlate with the severity of the motor deﬁcits and pathophysiological
changes in the nigrostriatal system and could be used as an indicator of
biological processes that change in response to dysfunction within the
cortico-basal-ganglia-cortical circuit.

2.2. Behavioral evaluation
All animals were extensively monitored and evaluated by nonbiased, objective, and non-invasive methods including an automated
video-tracking system (EthoVision Pro, Noldus Technologies, Asheville,
NC) and Actical accelerometers (MiniMitter, Bend, OR). Automated
Movement Tracking. The detailed procedures have been described elsewhere (Ding et al., 2008; Luan et al., 2008; Walton et al., 2006; Xin
et al., 2008). Brieﬂy, video recording procedures were conducted in
specially-designed cages located in a room adjacent to the housing
quarters. The tracking method relies on calibrating the software to the
dimensions of the cage, so that the position of the animal can be determined in the cage based on (x,y,z) coordinates. Behavioral values,
including distance traveled (cm) and movement velocity (cm/s) were
measured over the course of one hour. The same coded video records
were also used by trained observers to blindly evaluate parkinsonian
features using our nonhuman primate parkinsonian rating scale (Ding
et al., 2008; Ovadia et al., 1995). Actical accelerometers. Changes in
overall home-cage activity level were continuously monitored for each
monkey using activity monitors worn on collars. The monitors were
programmed to measure and store the activity counts at a one-minute
sample interval. Daily activity counts were recorded from 06 h00 (lights
ON) to 18 h00 (lights OFF) and nighttime levels were measured from
18 h00 to 06 h00.
2.3. Pharmacological MRI (phMRI)
Based on previously published procedures (Zhang et al., 2018), all
images were acquired on a Siemens 3 T Trio clinical MRI system using a
dedicated receive-only coil for reception, which was designed and developed by our group. Animals were maintained under general anesthesia (~1% isoﬂurane in oxygen) during image acquisitions. The
BOLD-eﬀect weighted MR images used to measure the phMRI response
were acquired in an anatomically coronal plane. The image planes of
the acquisition were arranged to cover the motor cortex and the basal
ganglia. A segmented gradient-echo EPI sequence with TE = 28 ms and
a turbo factor of 7 was used to reduce echo train length and minimize
susceptibility-related artifacts. The EPI sequence acquisition parameters
are FOV = 112 × 98 mm and image matrix 64 × 56 for an in-plane
resolution of 1.75 mm. A total of 15 contiguous slices, each 2 mm-thick,
were acquired at a rate of 15 s per EPI volume. The overall scan
duration was 80 min with 128 volumes acquired prior to APO administration (0.1 mg/kg injection S.C.) as a baseline and 192 volumes acquired after APO to track the response. APO was prepared daily in 0.9%
sterile saline 2 h before the scan. Images were motion corrected and
spatially smoothed using a Gaussian kernel of width 3.5 mm. phMRI
response was calculated as the fractional signal change in % of the
average of the post-APO image data relative to the pre-APO baseline. A
co-registered high-resolution (0.67 × 0.67 × 1 mm) T1-weighted anatomical MRI scan was acquired in each session for spatial localization of
the activation response.

2. Methods and materials
2.1. Animals
All procedures used in the study were approved by the University of
Kentucky Institutional Animal Care and Use Committee and followed
NIH and USDA guidelines. Six, late middle-aged (18 to 22 years old),
female rhesus monkeys (Macaca mulatta) expressing long-term hemiparkinsonism were used in the study. All animals were originally obtained from a commercial supplier (Covance, Alice, TX) and were
housed in a temperature-controlled room and maintained on a 12-h
light and 12-h dark cycle. Throughout the entire study, water was
available ad libitum and standard non-human primate biscuits were
supplemented daily with fresh fruits and vegetables.
Data were obtained within an 18-month period, approximately
3.5 years after the animals had been rendered hemiparkinsonian by a
unilateral administration of 0.12 mg/kg MPTP (1-methyl-4-phenyl1,2,3,6-tetrahydropyridine) via the right carotid artery. After MPTP
administration, all animals developed mild to moderate parkinsonian
features including bradykinesia, rigidity of upper and lower limbs on
the aﬀected side, stooped posture, and mild postural instability. Some
data shown here were previously reported and are recounted here to
describe the behavioral, histological, and neurochemical deﬁcits of

2.4. In vivo microdialysis of dopamine overﬂow
Measurement of both potassium- and d-amphetamine-induced DA
release was collected following previously published procedures from
each animal, after the PD features were fully developed and stable (Cass
et al., 2007; Gerhardt et al., 2002; Grondin et al., 2003). Brieﬂy,
custom-made CMA 11 dialysis probes with a membrane length of
3.0 mm and diameter of 0.24 mm (CMA Microdialysis, North Chelmsford, MA) were slowly lowered under sterile conditions into the putamen or SNc using MRI-derived stereotactic coordinates for each anesthetized animal. The probes were perfused at a ﬂow rate of 1.2 μl/min
with artiﬁcial CSF, and dialysate fractions were collected at 30-min
2
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Fig. 1. phMRI activation in diﬀerent structures between the MPTP-lesioned and unlesioned hemispheres. (A) caudate nucleus, (B) putamen, (C) primary motor
cortex, and (D) substantia nigra (SN). *p < 0.05, ** p < 0.01.

3.1. Post-mortem morphology

intervals. After a 1-h equilibration period, two baseline fractions were
collected and then overﬂow of DA was locally stimulated by reverse
microdialysis by switching to a perfusate solution containing elevated
potassium (100 mM) for a single 30-min fraction, then switching back
to the original perfusate for three additional fractions. A d-amphetamine (250 μM) stimulation was then included in the perfusate for one
30-min fraction followed by three ﬁnal fractions with normal artiﬁcial
CSF. Dialysate samples were assayed for DA after collection using HPLC
with electrochemical detection (Cass et al., 2003). Dialysis probe placement was conﬁrmed in each animal by structural MRI within 48–72 h
post-surgery.
Basal levels of DA were deﬁned as the average value of the two
fractions preceding stimulation by excess potassium. All probes were
calibrated in vitro prior to use to determine acceptable probes (recovery
of DA at least 15%). However, values were not corrected for in vitro
recoveries, as uncorrected values may be better correlated to true values (Glick et al., 1994). Dialysis data were expressed as nM concentration of DA or metabolite in the dialysate and, for evoked overﬂow, as the total amount of DA in the dialysate above baseline after
stimulation with potassium or d-amphetamine.

Immediately after the glutamate recordings, all animals were deeply
anesthetized with pentobarbital (20–25 mg/kg, IV) and euthanized via
transcardial perfusion with 0.9% saline based on previously published
procedures (Ding et al., 2008; Gash et al., 1996). The brains were immediately removed, immersion-ﬁxed in 4% paraformaldehyde solution
in 0.1 M phosphate buﬀer (pH 7.4) overnight and cryoprotected in 30%
buﬀered sucrose until they sank. Then, 40 μm-thick sections were cut
on a sliding microtome through the SN. Sections were processed for
tyrosine hydroxylase (TH, monoclonal antibody, 1:1000; Chemicon
International, Temecula, CA, USA) for assessment of TH-positive (TH+)
neuronal loss in the midbrain and loss of TH+ ﬁbers in the striatum
(procedures described elsewhere, Ding et al., 2008; Gash et al., 1996;
Grondin et al., 2002). The number of TH+ midbrain dopaminergic
neurons was estimated bilaterally using an optical fractionator method
for unbiased stereological cell counting. In addition, TH+ ﬁber density
was measured as percentage of area with TH+ immunoreactive staining
in both sides of the caudate nucleus and putamen of each hemisphere
and in each animal.
3.2. Statistical analysis

3. Electrochemical recordings of basal levels of glutamate
Statistical comparisons between the right (MPTP-lesioned) and left
hemispheres were treated as un-paired measurements as MPTP treatment profoundly aﬀects the structure and physiology of the eﬀected
hemisphere (Ding et al., 2008; Hamadjida et al., 2018). The phMRI data
used in the linear regression and correlation analyses were from the
hemisphere (right) on the ipsilateral side of MPTP administration. All
linear regressions were ﬁrst order, and two-tailed Pearson correlations
were used to identify relationships among behavioral, phMRI, or resting
glutamate features. Glutamate resting levels were analyzed from timeseries recordings in individual animals using custom MatLab®-based
analysis software, averaged from the multiple points in each animal,
and compared among animals at the group level using a Student's t-test.
The in vivo microdialysis results were initially analyzed using an
ANOVA followed by Newman–Keuls post hoc comparisons for the DA
response at individual time points. All statistical analyses were

Based on previously published procedures (Fan et al., 2014;
Quintero et al., 2007), the resting levels of glutamate were measured,
with biosensors, bilaterally in the primary motor cortex covering the
trunk and upper body regions (Fig. 4a) on the same day as necropsy.
Under general anesthesia (~1% isoﬂurane in oxygen), the skull directly
over the primary motor cortex was removed bilaterally to allow access
to the biosensors and a reference electrode (a Ag/AgCl electrode, Model
RE-5B, Bioanalytical Systems, West Lafayette, IN) was inserted into a
remote pocket (5 mm × 50 mm) in the area above the occipital lobes so
as to not interfere with the biosensors. Five diﬀerent points (2–3 mm
apart) from medial to lateral primary motor cortex were used on each of
the left and right sides of the cortex as illustrated in Fig. 4a. Resting
glutamate values for the right (MPTP-lesioned) and left cortices were
generated from an average of the last 30 s of the equilibration period.
3
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distance traveled (r2 = 0.68, P = 0.042) and the movement speed
(r2 = 0.69, P = 0.039). Similar relationships were also identiﬁed between phMRI responses in the motor cortex and the daytime home-cage
activity (r2 = 0.76, P = 0.02, Fig. 2C). APO-induced behavioral
changes in PD features were signiﬁcantly correlated with APO-induced
phMRI responses in the putamen (r2 = 0.72, P = 0.03, Fig. 2D), premotor cortex (r2 = 0.80, P = 0.015), and cingulate gyrus (r2 = 0.78,
P = 0.018).

conducted using Prism 6 or 7 GraphPad Software (San Diego, CA).
Diﬀerences of p < 0.05 were considered signiﬁcant.
4. Results
4.1. Dynamic phMRI response to APO
APO-evoked activations were observed in the caudate nucleus
(Unlesioned: 0.95 ± 0.04% phMRI activation vs. MPTP-lesioned:
1.62 ± 0.02% phMRI activation; P < 0.01, Fig. 1A) and putamen
(Unlesioned: 0.47 ± 0.37% phMRI activation vs. MPTP-lesioned:
1.11 ± 0.36% phMRI activation; P < 0.01, Fig. 1B). BOLD activation
induced by the APO challenge in the primary motor cortex was lower
but not signiﬁcantly diﬀerent (Unlesioned: 2.38 ± 0.13% phMRI activation vs. MPTP-lesioned: 2.12 ± 0.10% phMRI activation; P = 0.1;
Fig. 1C). The second novel observation was the reduction of BOLD
activation induced by the APO challenge in the SN (Unlesioned:
1.09 ± 0.12% phMRI activation vs. MPTP-lesioned: 0.35 ± 0.04%
phMRI activation; P < 0.01; Fig. 1D). The result in the SN diﬀers from
previous ﬁndings in short-term PD monkeys in which activation was
observed in the SN with lower doses of APO (Zhang et al., 2006).

4.2.2. Histopathology
A novel observation was the heterogeneous responses to APO
challenge in the putamen on the ipsilateral side of MPTP administration
(Fig. 3A). The greatest responses to APO in the MPTP-lesioned side
were observed in the more posterior sections (8–13) while the responses
in the last 2 sections (14–15) were smaller. Unbiased stereological cell
counts of TH+ dopamine neurons revealed > 85% loss of TH+ cells in
the MPTP-treated SN; and densitometry of TH+ ﬁber showed a signiﬁcant reduction of TH+ ﬁbers density in the MPTP-treated putamen.
Only 16.9% of dopaminergic ﬁbers remained compared with the contralateral side. The loss of TH+ terminals in the putamen was heterogeneous as shown by a greater loss in the posterior than anterior sections (Fig. 3B). The number of TH+ cells in the SNc was negatively
correlated with the phMRI-responses in the caudate nucleus (r2 = 0.75,
P = 0.026, Fig. 3C). In addition, TH+ ﬁber densities in the lesioned
putamen (r2 = 0.80, P = 0.016, Fig. 3D) and caudate nucleus
(r2 = 0.66, P = 0.048) were signiﬁcantly correlated with phMRI-responses seen in the primary motor cortex.

4.2. Correlations with phMRI
4.2.1. Behavior
All animals exhibited stable motor deﬁcits as judged by distance
traveled (Fig. 2A, Baseline: 10284 ± 503 cm vs. Post MPTP:
3060 ± 288 cm; P < 0.0001) and movement speed (Baseline:
2.9 ± 0.1 cm/s vs. Post MPTP: 1.5 ± 0.2 cm/s; P = 0.0002). In addition, all animals showed a positive response to APO (Fig. 2B). The total
PD score on the nonhuman primate parkinsonian scale improved by
over 40% post APO administration (Fig. 2B, MPTP without APO:
4.0 ± 0.6 points vs. MPTP with APO: 2.3 ± 0.4 points; P = 0.0075).
phMRI responses in the putamen were negatively correlated with the

4.2.3. Neurochemistry
The average of individual resting basal glutamate (5 sample sites in
each hemisphere) in the motor cortex was signiﬁcantly lower in the
MPTP-lesioned than the unlesioned hemisphere (Fig. 4A). Both potassium- and d-amphetamine-evoked overﬂow of DA in the putamen
(Fig. 4B) and SNc (Fig. C) on the ipsilateral side of the lesion were lower
Fig. 2. (A) Distance traveled between baseline and
after MPTP lesion showed a signiﬁcant (p < 0.001)
decrease in distance traveled after MPTP lesion. (B)
MPTP-treated animals showed characteristics associated with dopamine deﬁciency as measured with a
parkinsonian rating scale. Long-term, stable parkinsonian features improved with apomorphine treatment; **P < 0.01. (C) Home cage activity was inversely correlated with phMRI signals in the right
motor cortex. (D) Apomorphine-induced changes in
the parkinsonian rating scale was positively correlated with BOLD activation in the right (MPTPtreated side) putamen.

4
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Fig. 3. Areas of phMRI activation in the motor cortex
and basal ganglia in (A) after a 20 min APO chal), the pulenge. In the MPTP-lesioned side (
tamen shows areas of higher APO-induced BOLD
activation along the rostral-caudal axis than in the
unlesioned side (
). Sections were 3 mm in
thickness through the putamen. *p < 0.05. (B) TH+
ﬁber density distribution along the anterior-posterior
plane of the putamen in the MPTP-lesioned and the
unlesioned hemispheres. (C) BOLD-responses in the
right (MPTP-lesioned side) caudate were negatively
correlated with the number of TH+ cells in the right
substantia nigra. (D) BOLD-responses in the right
motor cortex were negatively correlated with TH+
ﬁbers in the right putamen.

parkinsonism may have occurred in parallel to the normalization of the
BOLD-signal in the motor cortex. (Hutchison et al., 1997; Stefani et al.,
1999; Stefani et al., 1997). Along these lines, human deep brain stimulation (DBS) studies have shown that acute administration of APO
causes a signiﬁcant decrease in cell ﬁring activity, which is paralleled
by amelioration of PD hypokinesia as assessed by an intraoperativelyadministered Uniﬁed Parkinson's Disease Rating Scale (UPDRS) examination. In a previously published study, hemiparkinsonian monkeys
were treated with oral L-dopa (250 to 500 mg) twice a day for 5 days.
We found that the treatment not only gradually and signiﬁcantly reduced the initial L-dopa-induced rotational behavior (observed in the
immediate days following L-dopa), but that the treatment also signiﬁcantly reduced the amplitude of L-dopa-induced BOLD activations in
the putamen (Chen et al., 1999). In a human phMRI study, signiﬁcant
correlations were demonstrated between the total motor UPDRS score
and BOLD activation in the striatum, subthalamic nucleus, external
segment of the globus pallidus and substantia nigra (Prodoehl et al.,
2010).
Another novel observation from the current study is that the BOLD
responses to APO administration were only observed in the putamen.
The heterogeneous BOLD response to APO matched the pattern of
heterogeneous changes of TH+ ﬁbers in the putamen. This ﬁnding
suggests that the BOLD responses to APO in the putamen could reﬂect
the histopathological severity of degeneration of the DA system. In
humans, postmortem analyses demonstrate heterogeneous changes in
the putamen with the greatest reductions of dopamine uptake sites
measured by [3H] mazindol binding located in the medial putamen
(Porritt et al., 2005). In addition, [18F] dopa uptake detected by PET
showed more severe loss of functional integrity of the nigrostriatal
dopaminergic neurons in the posterior putamen in patients with PD. We
believe that these ﬁndings could be attributed to the organization of the
basal ganglia, which represents a complex extrapyramidal motor
system, as opposed to the pyramidal motor system (corticobulbar and
corticospinal pathways). The basal ganglia-thalamocortical circuits
maintain somatotopic organization of movement-related neurons
throughout the circuit mainly through the putamen while the caudate

than the contralateral side. Basal glutamate levels in the primary motor
cortex were signiﬁcantly and negatively correlated with phMRI activation in the putamen (r2 = 0.87, P = 0.0064, Fig. 4D) and in the
premotor cortex (r2 = 0.83, P = 0.011). Both potassium- and d-amphetamine-evoked overﬂow of DA in the putamen (each measured for a
single time point, 30 min after stimulus administration) had signiﬁcant
correlations with phMRI responses in the putamen (data not shown).
Finally, d-amphetamine-evoked DA release in the SNc was found to
have a signiﬁcant, negatively correlated relationship with the phMRI
motor cortex activation (r2 = 0.74, P = 0.027, Fig. 4E).
5. Discussion
Here, we used phMRI to assess the function of the cortico-basal
ganglia circuit in a non-human primate model of dopamine deﬁciency
to determine the possible relationships between phMRI signals and DA
dysfunction. Our study supports a direct relationship between BOLDresponses and DA degeneration. First, BOLD-activation was highly
correlated with a number of measures, including: 1) potassium- and damphetamine-evoked DA release in the putamen, 2) the number of
surviving TH+ cells in the SNc, and 3) TH+ ﬁber density in the putamen. Moreover, TH+ ﬁbers density was also correlated with phMRI
responses in the putamen. These results are in line with those of a
previous phMRI study in parkinsonian rhesus monkeys (Zhang et al.,
2006)) in which phMRI responses to d-amphetamine were correlated
with surviving DA neurons in the midbrain. The results from this and
our previously published studies (Luan et al., 2008; Zhang et al., 2018;
Zhang et al., 2006) support the concept that phMRI could be a useful
tool for estimating the number of surviving DA neurons and terminals
in the nigrostriatal pathway, in a non-invasive manner. This could
provide pivotal information in assessing the disease state, the rate of
progressive cell loss rate, and the eﬀects of a disease modifying therapy
over time.
BOLD-activation was also highly correlated with DA-related behavioral deﬁcits. Because the same dose of APO was used for phMRI and
behavioral testing, we believe that the APO-induced improvements in
5
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Fig. 4. (A) Resting levels of glutamate were measured from 5 areas (2–3 mm apart) in the primary motor cortex from both the left and right hemispheres. Basal
glutamate levels in the ipsilateral motor cortex were signiﬁcantly lower than the contralateral motor cortex; P = 0.031. K+ (100 mM)- and amphetamine (250 μM)evoked DA release was signiﬁcantly attenuated in the ipsilateral (B) putamen (Put) and (C) SNc; ***P < 0.0001 – adapted from (Quintero et al., 2011). (D)
Glutamate levels in the right (MTP-lesioned side) motor cortex were inversely correlated with phMRI signals in the right putamen. (E) BOLD-responses in the right
motor cortex were negatively correlated with dopamine levels in the right subtantia nigra after amphetamine stimulation.

translation.
Another focus of this study was to investigate how BOLD-activation
in the motor cortex was associated with functional changes in other
areas of the cortico-nigrostriatal loops. The results from the present
study demonstrated that both dynamic BOLD-activations and basal
glutamate levels were reduced in the primary motor cortex on the ipsilateral side to the MPTP lesion suggesting that stronger activations
and higher glutamate levels were co-localized in the hemisphere contralateral to the MPTP administration. Few nonhuman primate studies
have been conducted to directly compare these two parameters, particularly in parkinsonian monkeys. Previously, in vivo fMRI has been
used to map the brain's hemodynamic responses to neuronal stimulations such as the susceptibility-based BOLD image contrast and the
change in regional CBF (rCBF) (Silva and Koretsky, 2002; Silva et al.,
1999; van Zijl et al., 1998). Results from those studies indicated that the
eﬀects of BOLD and rCBF appeared to reﬂect neuronal activity (Hoge
et al., 1999; Logothetis et al., 2001; Ogawa et al., 2000; Silva and
Koretsky, 2002), and were considered to be coupled tightly with

nucleus contributes to memory, learning, and cognitive functions, (for
reviews, see Alexander et al., 1986; Herrero et al., 2002). Moreover,
bradykinesia, which is a major clinical sign of PD, is more correlated
with the putamen than the caudate nucleus or SN (Prodoehl et al.,
2010).
In the current study, we selected late middle-aged animals because
PD is an age-associated neurodegenerative disease that infrequently
occurs before age 50 (Chu and Kordower, 2007; Ross et al., 2004;
Silver, 2006) with most patients being older than 60 years at the time of
diagnosis. Animals used for this study had ages ranging from 18 to
22 years old, which is the equivalent to ~54 to 66 years old in humans.
These animals displayed stable parkinsonian features for over 3 years
following the MPTP-treatments. A number of novel therapeutic strategies successfully tested in young parkinsonian monkeys have failed to
reach their endpoint when tested clinically in patients with PD (Chu
and Kordower, 2007). Thus, we hypothesize that this failure may be the
result, at least in part, from failing to test these therapies in older animals, which may represent a much more clinically relevant model for
6
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